Table 1.
Baseline demographic and disease characteristics.
| Characteristic | Placebo (n = 33) | Teriflunomide (n = 78) |
|---|---|---|
| Age, years | 14.6 (2.0) | 14.5 (2.1) |
| Female, n (%) | 25 (75.8) | 52 (66.7) |
| Pubertal status, n (%) | ||
| Prepubertal (Tanner stage 1) | 2 (6.1) | 5 (6.4) |
| Pubertal (Tanner stage > 1) | 31 (93.9) | 73 (93.6) |
| Number of relapses within past 1 year | 1.4 (0.7) | 1.6 (0.7) |
| Number of relapses within past 2 years | 1.9 (1.0) | 2.1 (1.0) |
| MS disease duration, years | 2.5 (2.3) | 2.3 (2.1) |
| Patients receiving MS medication in past 2 years, n (%) | 8 (24.2) | 10 (12.8) |
| Patients with Gd-enhancing lesions, n (%) | 14 (42.4) | 41 (53.9) |
| Number of Gd-enhancing lesions | 2.6 (6.3) | 4.1 (8.1) |
| T2 lesion volume, cm3 | 11.1 (11.1) | 13.1 (19.0) |
| Normalized brain volume, cm3 | 1556.7 (82.1) | 1542.5 (80.0) |
Values are mean (standard deviation) unless otherwise indicated. Disease duration was calculated as the difference between date of first MS symptoms and randomization date.
Gd = gadolinium; MS = multiple sclerosis.